Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 3.82 |
Low | 3.82 |
Bid | -- |
Offer | -- |
Previous close | 3.82 |
Average volume | -- |
---|---|
Shares outstanding | 871.56m |
Free float | 501.29m |
P/E (TTM) | -- |
Market cap | 24.32bn HKD |
EPS (TTM) | -0.3887 HKD |
Data delayed at least 15 minutes, as of Nov 17 2023 12:05 GMT.
More ▼
Announcements
- Appointment of Independent Non-executive Director
- HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
- Clinical Data to be Presented at ASH and ESMO Asia
- HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
- First Commercial Milestone Payment
- Total Voting Rights
- HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
- Vesting of awards under the LTIP
- SAVANNAH: clinically meaningful response rate
- HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
More ▼